Results 201 to 210 of about 195,293 (269)

Therapeutic Plasma Exchange: Current and Emerging Applications to Mitigate Cellular Signaling in Disease. [PDF]

Biomolecules
Rony RMIK, Shokrani A, Malhi NK, Hussey D, Mooney R, Chen ZB, Scott T, Han H, Moore J, Liu J, Huang W, Garcia-Ocaña A, Grant MB, Aboody K, Von Hoff D, Natarajan R, Tompkins JD.   +16 more
europepmc   +1 more source

Blue Toe Syndrome Responding to Direct Hemoadsorption Therapy with the Rheocarna^® Device. [PDF]

Intern Med
Nishiyama J, Aoyagi K, Tsuru K, Tsubaki S, Imamura S, Nagahama Y.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

LDL apheresis in Japan

Transfusion and Apheresis Science, 2017
LDL apheresis has been developed as the treatment for refractory familial hypercholesterolemia (FH). Currently, plasma exchange, double membrane filtration, and selective LDL adsorption are available in Japan, and selective LDL adsorption is most common method. LDL apheresis can prevent atherosclerosis progression even in homozygous (HoFH). However, in
Hisashi, Makino, Tamiko, Tamanaha, Mariko, Harada-Shiba   +2 more
openaire   +3 more sources

LDL Apheresis and Inflammation – Implications for Atherosclerosis

Scandinavian Journal of Immunology, 2012
AbstractLow‐density lipoprotein (LDL) apheresis is an extracorporeal treatment modality used in high‐risk patients when LDL cholesterol levels cannot be reduced adequately with medication. The treatment is highly effective, but could be affected by potential unwanted effects on pro‐ and anti‐inflammatory biomarkers.
A, Hovland, K T, Lappegård, T E, Mollnes   +2 more
openaire   +3 more sources

Low-Density Lipoprotein (LDL) Apheresis

2015
Low-density lipoprotein (LDL) apheresis, also referred to as lipoprotein apheresis or lipid apheresis, is a procedure that involves extracorporeal treatment of plasma to remove apoprotein (apo) B-containing lipoproteins followed by reinfusion of the processed blood.
P. Duell
openaire   +2 more sources

Efficacy of LDL apheresis for the treatment of cholesterol crystal embolism: A prospective, controlled study

Therapeutic apheresis and dialysis, 2021
This study was performed to evaluate the efficacy and safety of LDL apheresis (LDL‐A) for the treatment of cholesterol crystal embolism (CCE) after cardiovascular procedures.
K. Ishiyama, Toshinobu Sato
semanticscholar   +1 more source

LDL Apheresis

Transfusion Medicine and Hemostasis, 2019
Monika Paroder-Belenitsky, Huy P. Pham
openaire   +2 more sources

Hypercholesterolemia and LDL Apheresis

The International Journal of Artificial Organs, 2005
Several trials have assessed the link between low-density lipoprotein cholesterol (LDL) and the development of coronary heart disease (CHD). LDL apheresis provides an effective role in treating patients with familial hypercholesterolemia (FH) and in preventing the progression of coronary artery disease (CAD). Five different techniques of LDL apheresis
F. Morelli, P. Carlier, G. Giannini, M.C. De Luigi, A. Dejana, M.R. Ruzzenenti, M. Valbonesi   +6 more
openaire   +2 more sources

Immunosorbents for LDL-Apheresis

Biomaterials, Artificial Cells and Artificial Organs, 1990
Low density lipoprotein (LDL) (1,03-1,05 g/ml) was utilized as antigen to obtain polyclonal (PcAb) and monoclonal (McAb) antibodies. Immunosorbents capable of selective removing LDL from human plasma were developed on the basis of the antibodies preparation.
S N, Pokrovsky, , Adamova IYu, G F, Benevolenskaya   +2 more
openaire   +2 more sources

Changes in serum afamin and vitamin E levels after selective LDL apheresis

Journal of clinical apheresis, 2018
Afamin is a plasma vitamin E‐binding glycoprotein partially associated with ApoA1‐containing high‐density lipoprotein (HDL) subfractions. In a previous study, the serum vitamin E decreased after low‐density lipoprotein (LDL) apheresis, while vitamin E ...
V. Varga, H. Lőrincz, A. Szentpéteri, L. Juhász, I. Seres, G. Paragh, J. Balla, G. Paragh, M. Harangi   +8 more
semanticscholar   +1 more source